Name | Title | Contact Details |
---|---|---|
David DiGiusto |
Chief Technology Officer | Profile |
Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.
Nura Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioE is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.
Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases.